CD93 and central nervous system cancer: For gliomas, CD93 is currently considered as a possible therapeutic target since CD93-targeted therapy could significantly inhibit the growth and vascular perfusion of glioma in vivo by decreasing tumoral angiogenesis and repairing integrity of endothelial tight junctions (Langenkamp et al. 2015).